AL

Genoway SAPAR Genoway Stock Report

Last reporting period 30 Jun, 2023

Updated 08 Nov, 2024

Last price

Market cap $B

0.039

Micro

Exchange

XPAR - Euronext Paris

ALGEN.PA Stock Analysis

AL

Uncovered

Genoway SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

39/100

Low score

Market cap $B

0.039

Dividend yield

Shares outstanding

8.819 B

genOway SA engages in the development of genetically-modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.

View Section: Eyestock Rating